Necrotizing soft-tissue infections: Clinical guidelines

Journal of Burn Care and Research

Volumn 30, Issue 5, 2009, Pages 769-775

  Endorf, Frederick W ^a   Cancio, Leopoldo C ^b   Klein, Matthew B ^c  

^a REGIONS HOSPITAL   (United States)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; VANCOMYCIN;

DEBRIDEMENT; ENTERIC FEEDING; EVIDENCE BASED MEDICINE; HUMAN; HYPERBARIC OXYGEN; NECROTIZING FASCIITIS; NECROTIZING SOFT TISSUE INFECTION; NONHUMAN; OXIDATION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SOFT TISSUE INFECTION; TISSUE NECROSIS;

ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CLINDAMYCIN; DEBRIDEMENT; ENTERAL NUTRITION; FASCIITIS, NECROTIZING; GANGRENE; HUMANS; HYPERBARIC OXYGENATION; RISK FACTORS; VACUUM; VANCOMYCIN;

EID: 70349658523     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181b48321     Document Type: Review

References (41)

1. Faucher LD, Morris SE, Edelman LS, Saffle JR. Burn center management of necrotizing soft-tissue surgical infections in unburned patients. Am J Surg 2001;182:563-569
2. Barillo DJ, McManus AT, Cancio LC, Sofer A, Goodwin CW. Burn center management of necrotizing fasciitis. J Burn Care Rehab 2003;24:127-132
3. Endorf FW, Supple KG, Gamelli RL. The evolving characteristics and care of necrotizing soft-tissue infections. Burns 2005;31:269-273
4. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-862
5. Mehta S, McGeer A, Low DE, et al. Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 2006;130:1679-1686
6. Golger A, Ching S, Goldsmith CH, Pennie RA, Bain JR. Mortality in patients with necrotizing fasciitis. Plast Reconstr Surg 2007;119:1803-1807
7. Widjaja AB, Tran A, Cleland H, Leung M, Millar I. The hospital costs of treating necrotizing fasciitis. ANZ J Surg 2005;75:1059-1064
8. Endorf FW, Klein MB, Mack C, Jurkovich GJ, Rivara FP. Necrotizing soft-tissue infections: Differences in patients at burn centers and non-burn centers. J Burn Care Res 2008; 29:933-938
9. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 1996;224:672-683
10. Miller AT, Saadai P, Greenstein A, Divino CM. Postprocedural necrotizing fasciitis: A 10-year retrospective review. Am Surg 2008;74:405-409
11. Wong C, Chang H, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: Clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003;85: 1454-1460
12. Wong CH, Wang YS. The diagnosis of necrotizing fasciitis. Curr Opin Infect Dis 2005;18:101-106
13. Wall DB, Klein SR, Black S, de Virgilio C. A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg 2000;191:227-231 (Pubitemid 30676767)
14. Anaya DA, McMahon K, Nathens AB, Sullivan SR, Foy H, Bulger E. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005;140:151-157
15. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: A tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32: 1535-1541
16. Yaghoubian A, de Virgilio C, Dauphine C, Lewis RJ, Lin M. Use of admission serum lactate and sodium levels to predict mortality in necrotizing soft-tissue infections. Arch Surg 2007;142:840-846
17. Yilmazlar T, Ozturk E, Alsoy A, Ozguc H. Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg 2007;31:1858-1862
18. Brandt MM, Corpron CA, Wahl WL. Necrotizing soft tissue infections: A surgical disease. Am Surg 2000;66:967-970
19. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive management of necrotizing fasciitis serves to decrease mortality: A retrospective study. Am Surg 1998;64:397-401; discussion 400-401
20. Gallup DG, Freedman MA, Meguiar RV, Freedman SN, Nolan TE. Necrotizing fasciitis in gynecologic and obstetric patients: A surgical emergency. Am J Obstet Gynecol 2002;187:305-11; discussion 310-311
21. Heinle EC, Dougherty WR, Garner WL, Reilly DA. The use of 5% mafenide acetate solution in the postgraft treatment of necrotizing fasciitis. J Burn Care Rehab 2001;22:35-40.
22. De Geus HRH, Van der Klooster JM. Vacuum-assisted closure in the treatment of large skin defects due to necrotizing fasciitis. Intensive Care Med 2005;31:601.
23. Bronchard R, de Vaumas C, Lasocki S, et al. Vacuum-assisted closure in the treatment of perineal necrotizing skin and soft tissue infections. Intensive Care Med 2008;34:1345-1347
24. Akhtar S, Hasham S, Abela C, Phipps AR. The use of Integra in necrotizing fasciitis. Burns 2006;32:251-254
25. Muangman P, Engrav LH, Heimbach DM, et al. Complex wound management utilizing an artificial dermal matrix. Ann Plast Surg 2006;57:199-202.
26. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990;108:847-850
27. Korhonen K. Hyperbaric oxygen therapy in acute necrotizing infections. With a special reference to the effects on tissue gas tensions. Ann Chir Gynaecol 2000;89:7-36.
28. Escobar SJ, Slade JB Jr, Hunt TK, Cianci P. Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate. Undersea Hyperb Med 2005;32:437-443
29. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S. Necrotizing fasciitis: An indication for hyperbaric oxygen therapy? Surgery 1995;118:873-878
30. Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A Streptococci. Int J Antimicrob Agents 2001;18:395-398
31. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18:1096-1100
32. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007;13:1510-1514
33. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: When the infection is more than skin deep. J Antimicrob Chemother 2004;53(Suppl 2):ii37-ii50.
34. Norrby-Teglund A, Muller MP, Mcgeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005;37: 166-172
35. Cawley MJ, Briggs M, Haith LR Jr, et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: Case report and review. Pharmacotherapy 1999;19:1094-1098
36. Simmonds M. Necrotising fasciitis and group A streptococcus toxic shock-like syndrome in pregnancy: Treatment with plasmapheresis and immunoglobulin. Int J Obstet Anesth 1999;8:125-130
37. Purnell D, Hazlett T, Alexander SL. A new weapon against severe sepsis related to necrotizing fasciitis. Dimens Crit Care Nurs 2004;23:18-23.
38. Graves C, Saffle J, Morris S, Sauffer T, Edelman L. Caloric requirements in patients with necrotizing fasciitis. Burns 2005;31:55-59
39. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002;8: 1398-1404
40. Walker MJ, Hollands A, Sanderson-Smith ML, et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007;13:981-985
41. Johansson L, Thulin P, Sendi P, et al. Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun 2008;76:3399-3404